These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 28216000)

  • 1. Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2017 Mar; 115():115-127. PubMed ID: 28216000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2016 Dec; 111():253-265. PubMed ID: 27590915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of allosteric modulation: Exploring the binding kinetics of glutamate and other orthosteric ligands of the metabotropic glutamate receptor 2.
    Doornbos MLJ; Vermond SC; Lavreysen H; Tresadern G; IJzerman AP; Heitman LH
    Biochem Pharmacol; 2018 Sep; 155():356-365. PubMed ID: 30028996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators.
    Lundström L; Bissantz C; Beck J; Wettstein JG; Woltering TJ; Wichmann J; Gatti S
    Br J Pharmacol; 2011 Sep; 164(2b):521-37. PubMed ID: 21470207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
    J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the developement of positive allosteric modulators of the metabotropic glutamate receptor 2.
    Trabanco AA; Cid JM; Lavreysen H; Macdonald GJ; Tresadern G
    Curr Med Chem; 2011; 18(1):47-68. PubMed ID: 21110815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of essential residues involved in the glutamate binding pocket of the group II metabotropic glutamate receptor.
    Malherbe P; Knoflach F; Broger C; Ohresser S; Kratzeisen C; Adam G; Stadler H; Kemp JA; Mutel V
    Mol Pharmacol; 2001 Nov; 60(5):944-54. PubMed ID: 11641422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA.
    Lundström L; Kuhn B; Beck J; Borroni E; Wettstein JG; Woltering TJ; Gatti S
    ChemMedChem; 2009 Jul; 4(7):1086-94. PubMed ID: 19402024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
    Litim N; Morissette M; Di Paolo T
    Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
    Galici R; Echemendia NG; Rodriguez AL; Conn PJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology.
    Gregory KJ; Nguyen ED; Reiff SD; Squire EF; Stauffer SR; Lindsley CW; Meiler J; Conn PJ
    Mol Pharmacol; 2013 May; 83(5):991-1006. PubMed ID: 23444015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive allosteric modulation reveals a specific role for mGlu2 receptors in sensory processing in the thalamus.
    Copeland CS; Neale SA; Salt TE
    J Physiol; 2012 Feb; 590(4):937-51. PubMed ID: 22199165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
    Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
    Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mGlu(2) receptor-mediated modulation of conditioned avoidance behavior in rats.
    Megens AA; Hendrickx HM; Hens KA; Talloen WJ; Lavreysen H
    Eur J Pharmacol; 2014 Mar; 727():130-9. PubMed ID: 24486391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
    Niswender CM; Jones CK; Lin X; Bubser M; Thompson Gray A; Blobaum AL; Engers DW; Rodriguez AL; Loch MT; Daniels JS; Lindsley CW; Hopkins CR; Javitch JA; Conn PJ
    ACS Chem Neurosci; 2016 Sep; 7(9):1201-11. PubMed ID: 27441572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.
    Dhanya RP; Sheffler DJ; Dahl R; Davis M; Lee PS; Yang L; Nickols HH; Cho HP; Smith LH; D'Souza MS; Conn PJ; Der-Avakian A; Markou A; Cosford ND
    J Med Chem; 2014 May; 57(10):4154-72. PubMed ID: 24735492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
    Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
    J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture.
    Ahnaou A; Dautzenberg FM; Geys H; Imogai H; Gibelin A; Moechars D; Steckler T; Drinkenburg WH
    Eur J Pharmacol; 2009 Jan; 603(1-3):62-72. PubMed ID: 19046965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
    Sanger H; Hanna L; Colvin EM; Grubisha O; Ursu D; Heinz BA; Findlay JD; Vivier RG; Sher E; Lodge D; Monn JA; Broad LM
    Neuropharmacology; 2013 Mar; 66():264-73. PubMed ID: 22659090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.